Article

Anti-PDGF, anti-VEGF combination demonstrates superior efficacy for wet AMD

Results from a phase IIb, prospective, randomized, double-masked clinical trial of treatment for neovascular age-related macular degeneration (AMD) show significantly better improvement in visual acuity among patients receiving combination therapy with Fovista (formerly known as E10030, Ophthotech), an investigational pegylated aptamer directed against platelet-derived growth factor subunit B (PDGF-B), plus ranibizumab (Lucentis, Genentech) compared with a parallel control group receiving ranibizumab alone.

Princeton, NJ-Results from a phase IIb, prospective, randomized, double-masked clinical trial of treatment for neovascular age-related macular degeneration (AMD) show significantly better improvement in visual acuity among patients receiving combination therapy with Fovista (formerly known as E10030, Ophthotech), an investigational pegylated aptamer directed against platelet-derived growth factor subunit B (PDGF-B), plus ranibizumab (Lucentis, Genentech) compared with a parallel control group receiving ranibizumab alone.

The study enrolled 449 patients with subfoveal neovascular AMD and randomly assigned them into three arms to receive monthly intravitreal injections of ranibizumab 0.5 mg plus Fovista 0.3 mg, ranibizumab 0.5 mg plus Fovista 1.5 mg, or ranibizumab 0.5 mg plus sham. Mean gain in ETDRS visual acuity at week 24 was assessed as the primary efficacy endpoint.

The results showed a dose-response benefit for Fovista and statistically significant superiority comparing the combination of Fovista 1.5 mg and ranibizumab versus sham plus ranibizumab. Mean gain in ETDRS visual acuity was 10.6 letters for patients treated with the higher dose of Fovista in combination with ranibizumab and 6.5 letters for controls receiving ranibizumab monotherapy (p = 0.019).

Visual acuity data from earlier visits showed better outcomes in the group receiving Fovista 1.5 mg plus ranibizumab compared with the patients who received ranibizumab monotherapy at all monthly intervals, and the magnitude of the difference between groups increased with time, suggesting a benefit of continuing combination therapy with the anti-PDGF and anti-vascular endothelial growth factor agents. There were no significant safety issues identified during the 6 months of follow-up.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.